A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase 1 study to determine the effect of oral TR-701 FA on SBP response when administered with tyramine

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Trius Therapeutics LLC
• Treatments: Tedizolid; Tedizolid phosphate; Torezolid phosphate; Tyramine

Criteria

Inclusion Criteria:

• Male or female subjects between 18 to 45 years of age, inclusive

• Body mass index between 19 kg/m2 and 31 kg/m2, inclusive

• Healthy subjects with no clinically significant abnormalities identified by a detailed medical history,

Exclusion Criteria:

• Systolic blood pressure >130 mmHg or <90 mmHg measured after 10 minutes in the supine position at Screening or at admission to the study center

• Heart rate >90 bpm or <45 bpm measured after 10 minutes in the supine position

• Electrocardiogram (ECG) finding of QTc interval >500 msec, or other clinically significant ECG abnormality at the Screening Visit